[{"id":"dafa2925-32f3-4c57-916b-ccb5ee13aa7f","acronym":"FRIDA","url":"https://clinicaltrials.gov/study/NCT02370238","created_at":"2021-01-18T11:17:27.837Z","updated_at":"2024-07-02T16:36:03.814Z","phase":"Phase 2","brief_title":"A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT02370238 - FRIDA","lead_sponsor":"Dompé Farmaceutici S.p.A","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • reparixin (DF 1681Y)"],"overall_status":"Completed","enrollment":" Enrollment 194","initiation":"Initiation: 07/29/2015","start_date":" 07/29/2015","primary_txt":" Primary completion: 02/20/2019","primary_completion_date":" 02/20/2019","study_txt":" Completion: 03/23/2020","study_completion_date":" 03/23/2020","last_update_posted":"2022-09-16"},{"id":"d4991b18-5406-47c3-b13e-fa583d6baff0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02001974","created_at":"2021-01-18T09:08:28.016Z","updated_at":"2024-07-02T16:36:23.962Z","phase":"Phase 1","brief_title":"Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)","source_id_and_acronym":"NCT02001974","lead_sponsor":"Dompé Farmaceutici S.p.A","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • reparixin (DF 1681Y)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 02/27/2012","start_date":" 02/27/2012","primary_txt":" Primary completion: 06/25/2014","primary_completion_date":" 06/25/2014","study_txt":" Completion: 01/15/2015","study_completion_date":" 01/15/2015","last_update_posted":"2021-09-27"}]